TY - JOUR
T1 - Hypolipaemic and haemorheologic effects of coenzyme a (CoAlip* * CoAlip, ISF SpA, Trezzano S.N., Milan, Italy.) in patients with various types of dyslipidaemia
AU - Altomare, E.
AU - Stufano, N.
AU - Vendemiale, G. L.
AU - Albano, O.
AU - Fraticelli, G.
PY - 1987
Y1 - 1987
N2 - Twenty-two patients with cholesterotaemia and/or triglyceridaemia with blood lipid values exceeding normal (dyslipoproteinaemia Types IIa, IIb and IV) were treated for 20 days with Coenzyme A (CoA), given intravenously as a single daily dose of 2000 Lipmann Units. The aim of the study was to determine whether CoA reduced lipidaemic values in dyslipoproteinaemic patients, and whether this reduction was accompanied by improved erythrocyte shape flexibility as measured by Reid's test. The results of the study confirm that the normalizing effect of CoA is evenly spread among all the parameters of modified lipid metabolism, the time between administration and onset of activity being short. CoA therapy also resulted in greater erythrocyte shape flexibility in the patients examined, consequently with enhanced tissue oxygenation. No side-effects were recorded, confirming that the tolerability of CoA, a physiological substance, is excellent.
AB - Twenty-two patients with cholesterotaemia and/or triglyceridaemia with blood lipid values exceeding normal (dyslipoproteinaemia Types IIa, IIb and IV) were treated for 20 days with Coenzyme A (CoA), given intravenously as a single daily dose of 2000 Lipmann Units. The aim of the study was to determine whether CoA reduced lipidaemic values in dyslipoproteinaemic patients, and whether this reduction was accompanied by improved erythrocyte shape flexibility as measured by Reid's test. The results of the study confirm that the normalizing effect of CoA is evenly spread among all the parameters of modified lipid metabolism, the time between administration and onset of activity being short. CoA therapy also resulted in greater erythrocyte shape flexibility in the patients examined, consequently with enhanced tissue oxygenation. No side-effects were recorded, confirming that the tolerability of CoA, a physiological substance, is excellent.
KW - Coenzyme A
KW - Dyslipoproteinaemia
KW - erythrocyte shape flexibility
KW - Reid's test
UR - http://www.scopus.com/inward/record.url?scp=0023232137&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0023232137&partnerID=8YFLogxK
M3 - Article
AN - SCOPUS:0023232137
VL - 24
SP - 254
EP - 264
JO - Clinical Trials Journal
JF - Clinical Trials Journal
SN - 0009-9325
IS - 3
ER -